NanoHybrid is a technology platform based on proprietary, ready-to-use nano reagents enabling the instantaneous detection of protein biomarkers (such as antibodies) in complex biological matrices such as blood serum.
NanoHybrid-based tests are quick and easy homogeneous assays based on fluorescence readout.
We develop next generation, tailored fluorescent nano-sensors with improved properties in terms of scalability, flexibility, stability and multifunctionality.
NanoHybrid is a green and sustainable platform, that allows to use fewer plastic wares compared to traditional assays.
Add reporter buffer
Add your samples
Add activator reagent
NanoHybrid platform can be implemented to develop diagnostic as well as theranostics solutions – i.e., the integration of a diagnostic method with a specific therapeutic intervention aimed to maximize drug effectiveness – as well as vaccine/immunotherapies monitoring.
NanoHybrid can represent an effective alternative to ELISA (Enzyme Linked Immuno-Sorbent Assay), currently considered the gold standard in immunological diagnostics, and to rapid lateral flow tests for portable diagnostics (POC), by overcoming main drawbacks of these conventional assays.
NanoHybrid is composed by two or more nano-switch modular structures. The reporter and input modules are both conjugated through a composable PNA linker structure with a binding moiety for the antibody of interest (i.e., an antigen). The biomarker present in patient’s serum (i.e., an antibody) binds to the binding moieties bringing the two modules in close proximity. Due do the increase in local concentration, annealing of the light blue segments is favored, consequently unwinding the hairpin. The conformational change displaces the fluorophore away from the quencher, allowing the emission of fluorescent signal, which is proportional to the antibody amount.